Latest news
Loading news…
Amicus Therapeutics
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 MediumHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Cranbury, New Jersey, United States Founded 2002 251-500 employees For Profit
Amicus Therapeutics is a biotechnology company that discovers, develops, and commercializes treatments for rare and genetic diseases
Amicus Therapeutics was acquired by BioMarin Pharmaceutical in 2025 for $4.8B.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
3
Monthly Visits
Available in Pro Contacts
0
Ticker
FOLD
NASDAQ
Patents
248
38 trademarks
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Public
- Ticker
- FOLD
- Exchange
- NASDAQ
- IPO date
- May 31, 2007
- Raised at IPO
- $315M
- Valuation at IPO
- $330M
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 32
- Active products
- 24
- Patents granted
- 248
- Trademarks
- 38
- Top patent class
- Medical Or Veterinary Science; Hygiene
- IT spend
- $13.76M
Company Info
- Founded
- 2002
- Employees
- 251-500
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 1
- News articles
- 428
- HQ
- Cranbury, New Jersey, United States
- Region
- Greater New York Area, East Coast, Northeastern US
- Exit date
- May 31, 2007
Signals & Scores
- Heat score
- Medium
- Growth score
- Low
- Trend (7d)
- -0.6
- Trend (30d)
- -2
- Trend (90d)
- 4
- Last leadership hire
- Aug 21, 2023
- Last layoff mention
- May 13, 2026
Acquisitions by Amicus Therapeutics
Loading columns…
0 of 0Show
Page 1 / 1
Key People at Amicus Therapeutics
Chief Science Officer
Chief Patient Advocate
Chief Development Officer
President & Chief Executive Officer
Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Amicus Therapeutics
Loading news…
FAQs about Amicus Therapeutics
People who checked this page also checked these
Sectors Amicus Therapeutics invests & acquires in
Browse the full Acquirezy directory.